APA

Makker V., Recio F. O., Ma L., Matulonis U. A., Lauchle J. O., Parmar H., Gilbert H. N., Ware J. A., Zhu R., Lu S., Huw L., Wang Y., Koeppen H., Spoerke J. M., Lackner M. R. & Aghajanian C. A. (2016). A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). : Cancer.

Chicago

Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R and Aghajanian Carol A. 2016. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). : Cancer.

Harvard

Makker V., Recio F. O., Ma L., Matulonis U. A., Lauchle J. O., Parmar H., Gilbert H. N., Ware J. A., Zhu R., Lu S., Huw L., Wang Y., Koeppen H., Spoerke J. M., Lackner M. R. and Aghajanian C. A. (2016). A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). : Cancer.

MLA

Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R and Aghajanian Carol A. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). : Cancer. 2016.